[{"id":"897414a3-bc36-4d90-b0c6-902256e6b2d3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02334865","created_at":"2021-02-24T21:53:04.763Z","updated_at":"2025-02-25T14:35:10.773Z","phase":"Phase 1","brief_title":"SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy","source_id_and_acronym":"NCT02334865","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02 • HLA-A*24","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • SurVaxM (SVN53-67/M57-KLH peptide vaccine) • Leukine (sargramostim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 04/13/2017","start_date":" 04/13/2017","primary_txt":" Primary completion: 09/16/2022","primary_completion_date":" 09/16/2022","study_txt":" Completion: 05/19/2026","study_completion_date":" 05/19/2026","last_update_posted":"2024-06-04"},{"id":"ae21f239-5ecf-43a4-82a8-5216e3c17404","acronym":"","url":"https://clinicaltrials.gov/study/NCT02297698","created_at":"2021-01-18T10:50:01.049Z","updated_at":"2024-07-02T16:35:26.527Z","phase":"Phase 2","brief_title":"Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients","source_id_and_acronym":"NCT02297698","lead_sponsor":"Cancer Insight, LLC","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HLA-A*24","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Leukine (sargramostim) • NeuVax (nelipepimut-S)"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2023-12-12"},{"id":"fd14e8af-6cb8-4bd3-b1fb-c8845a7616b6","acronym":"SAFE-T-HBV","url":"https://clinicaltrials.gov/study/NCT04745403","created_at":"2022-07-02T01:54:42.621Z","updated_at":"2024-07-02T16:35:28.875Z","phase":"Phase 1","brief_title":"Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)","source_id_and_acronym":"NCT04745403 - SAFE-T-HBV","lead_sponsor":"Lion TCR Pte. Ltd.","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02 • HLA-A*24:02 • HLA-A*24","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A*24:02 • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LioCyx-M"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 05/20/2022","start_date":" 05/20/2022","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2023-11-17"},{"id":"30e6b0d2-9ae8-42e8-950a-d7ffc20b493b","acronym":"WIZARD201G","url":"https://clinicaltrials.gov/study/NCT03149003","created_at":"2021-06-30T14:53:13.951Z","updated_at":"2024-07-02T16:35:29.166Z","phase":"Phase 3","brief_title":"A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy","source_id_and_acronym":"NCT03149003 - WIZARD201G","lead_sponsor":"Sumitomo Pharma America, Inc.","biomarkers":" MGMT • HLA-A","pipe":" | ","alterations":" HLA-A*02 • HLA-A*24:02 • HLA-A*24","tags":["MGMT • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A*24:02 • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • adegramotide/nelatimotide (DSP-7888)"],"overall_status":"Completed","enrollment":" Enrollment 221","initiation":"Initiation: 12/08/2017","start_date":" 12/08/2017","primary_txt":" Primary completion: 08/30/2021","primary_completion_date":" 08/30/2021","study_txt":" Completion: 08/30/2021","study_completion_date":" 08/30/2021","last_update_posted":"2023-11-15"},{"id":"552ca11f-790a-4b84-becf-793c8ecee83b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02498665","created_at":"2021-01-18T12:02:59.664Z","updated_at":"2024-07-02T16:35:29.249Z","phase":"Phase 1","brief_title":"A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies","source_id_and_acronym":"NCT02498665","lead_sponsor":"Sumitomo Pharma America, Inc.","biomarkers":" HLA-A • MUC16","pipe":" | ","alterations":" HLA-A*02 • HLA-A*24","tags":["HLA-A • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e adegramotide/nelatimotide (DSP-7888)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 08/01/2018","primary_completion_date":" 08/01/2018","study_txt":" Completion: 09/01/2018","study_completion_date":" 09/01/2018","last_update_posted":"2023-11-14"},{"id":"95852f2d-c3f9-49a8-9023-dcdaab70f2d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02750891","created_at":"2021-01-18T13:28:43.111Z","updated_at":"2024-07-02T16:36:13.147Z","phase":"Phase 1/2","brief_title":"A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas","source_id_and_acronym":"NCT02750891","lead_sponsor":"Sumitomo Pharma Co., Ltd.","biomarkers":" PD-L1 • WT1","pipe":" | ","alterations":" PD-L1 expression • HLA-A*24","tags":["PD-L1 • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e adegramotide/nelatimotide (DSP-7888)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 01/01/2020","study_completion_date":" 01/01/2020","last_update_posted":"2022-04-12"},{"id":"d14351b0-6a7c-4a76-937b-a44735e97526","acronym":"","url":"https://clinicaltrials.gov/study/NCT02436252","created_at":"2021-02-01T11:52:50.145Z","updated_at":"2024-07-02T16:36:13.189Z","phase":"Phase 1/2","brief_title":"Study of DSP-7888 in Patients With Myelodysplastic Syndrome","source_id_and_acronym":"NCT02436252","lead_sponsor":"Sumitomo Pharma Co., Ltd.","biomarkers":" HLA-A • WT1","pipe":" | ","alterations":" HLA-A*02 • HLA-A*24","tags":["HLA-A • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e adegramotide/nelatimotide (DSP-7888)"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 03/01/2020","study_completion_date":" 03/01/2020","last_update_posted":"2022-04-12"},{"id":"65ccaf9d-1aaa-48e3-98b4-14d4e6be1110","acronym":"","url":"https://clinicaltrials.gov/study/NCT02096614","created_at":"2021-01-18T09:40:44.722Z","updated_at":"2024-07-02T16:36:28.955Z","phase":"Phase 1","brief_title":"Investigator Initiated Phase 1 Study of TBI-1201","source_id_and_acronym":"NCT02096614","lead_sponsor":"Mie University","biomarkers":" MAGEA4","pipe":" | ","alterations":" MAGEA4 expression • HLA-A*24","tags":["MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MAGEA4 expression • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TBI 1201 • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 03/01/2021","primary_completion_date":" 03/01/2021","study_txt":" Completion: 03/01/2021","study_completion_date":" 03/01/2021","last_update_posted":"2021-06-18"},{"id":"56840cd1-de4a-4f57-9498-f5727132e914","acronym":"","url":"https://clinicaltrials.gov/study/NCT04418219","created_at":"2021-01-18T21:17:41.922Z","updated_at":"2024-07-02T16:36:29.480Z","phase":"Phase 1/2","brief_title":"Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer","source_id_and_acronym":"NCT04418219","lead_sponsor":"Thomas Jefferson University","biomarkers":" HER-2 • PD-L1 • ER • PGR • PD-L2 • HLA-B • PRAME • HLA-C","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • ER positive • HER-2 negative • ER positive + PGR positive • PGR positive • PGR negative • HLA-A*24","tags":["HER-2 • PD-L1 • ER • PGR • PD-L2 • HLA-B • PRAME • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • ER positive • HER-2 negative • ER positive + PGR positive • PGR positive • PGR negative • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • Bria-IMT (SV-BR-1-GM) • cyclophosphamide intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/21/2020","start_date":" 12/21/2020","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2021-06-07"},{"id":"2ad2c325-cb2d-4eac-988b-e223d359b314","acronym":"","url":"https://clinicaltrials.gov/study/NCT03203005","created_at":"2021-06-30T14:53:18.228Z","updated_at":"2024-07-02T16:36:50.444Z","phase":"Phase 1/2","brief_title":"IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients","source_id_and_acronym":"NCT03203005","lead_sponsor":"National Cancer Institute, Naples","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02 • HLA-A*24","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CV8102 • Hepavac (IMA970A) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 09/18/2017","start_date":" 09/18/2017","primary_txt":" Primary completion: 12/20/2019","primary_completion_date":" 12/20/2019","study_txt":" Completion: 12/20/2019","study_completion_date":" 12/20/2019","last_update_posted":"2020-02-05"},{"id":"f5fa0587-a42c-4ae9-b704-89c0b50791d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02709993","created_at":"2021-01-18T13:14:51.985Z","updated_at":"2024-07-02T16:36:54.629Z","phase":"Phase 1/2","brief_title":"Consolidation Therapy in Patients With Hematologic Malignancies","source_id_and_acronym":"NCT02709993","lead_sponsor":"Kiromic, Inc.","biomarkers":" HLA-A • PTTG1","pipe":" | ","alterations":" HLA-A*02 • HLA-A*24","tags":["HLA-A • PTTG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • BSK-01"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/28/2017","start_date":" 07/28/2017","primary_txt":" Primary completion: 10/31/2020","primary_completion_date":" 10/31/2020","study_txt":" Completion: 10/31/2020","study_completion_date":" 10/31/2020","last_update_posted":"2019-10-14"},{"id":"292a3dbb-b477-4dfa-9565-daad0a56598c","acronym":"da VINci","url":"https://clinicaltrials.gov/study/NCT03784040","created_at":"2021-01-18T18:42:48.795Z","updated_at":"2025-02-25T14:27:54.363Z","phase":"Phase 1","brief_title":"Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study.","source_id_and_acronym":"NCT03784040 - da VINci","lead_sponsor":"National University Hospital, Singapore","biomarkers":" PD-L1","pipe":" | ","alterations":" HLA-A*24","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • OTSGC-A24"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/21/2019","start_date":" 02/21/2019","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2019-04-08"},{"id":"35ecd9e1-5591-4a15-9b32-e32d19fcfd20","acronym":"","url":"https://clinicaltrials.gov/study/NCT02705703","created_at":"2021-01-18T13:12:40.330Z","updated_at":"2024-07-02T16:37:07.408Z","phase":"Phase 1/2","brief_title":"Consolidation Therapy in Patients With Metastatic Solid Malignancies","source_id_and_acronym":"NCT02705703","lead_sponsor":"Kiromic, Inc.","biomarkers":" HER-2 • HLA-A • CTAG1B","pipe":" | ","alterations":" HER-2 expression • HLA-A*02 • HLA-A*24","tags":["HER-2 • HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • HLA-A*02 • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • BSK-01"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/28/2017","start_date":" 07/28/2017","primary_txt":" Primary completion: 10/31/2018","primary_completion_date":" 10/31/2018","study_txt":" Completion: 01/31/2019","study_completion_date":" 01/31/2019","last_update_posted":"2018-08-28"},{"id":"df1c5be5-ccb4-434c-b932-cc2846caf32a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02223312","created_at":"2021-01-18T10:25:19.825Z","updated_at":"2024-07-02T16:37:07.453Z","phase":"Phase 1/2","brief_title":"Therapy for Progressive and/or Refractory Hematologic Malignancies","source_id_and_acronym":"NCT02223312","lead_sponsor":"Kiromic, Inc.","biomarkers":" CSF2 • PTTG1","pipe":" | ","alterations":" HLA-A*24","tags":["CSF2 • PTTG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • BSK-01"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/28/2017","start_date":" 07/28/2017","primary_txt":" Primary completion: 10/31/2018","primary_completion_date":" 10/31/2018","study_txt":" Completion: 01/31/2019","study_completion_date":" 01/31/2019","last_update_posted":"2018-08-28"},{"id":"6e2d07bb-ff82-4aba-b019-e034b92f6ad5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02149225","created_at":"2021-01-18T09:59:12.536Z","updated_at":"2024-07-02T16:37:08.190Z","phase":"Phase 1","brief_title":"GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients","source_id_and_acronym":"NCT02149225","lead_sponsor":"Immatics Biotechnologies GmbH","biomarkers":" HLA-A • CSF2","pipe":" | ","alterations":" HLA-A*02 • HLA-A*24","tags":["HLA-A • CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • APVAC1 vaccine • Hiltonol (poly-ICLC) • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 06/01/2018","study_completion_date":" 06/01/2018","last_update_posted":"2018-08-07"},{"id":"f5fd43a8-c358-4b19-914b-50f3d0b72feb","acronym":"","url":"https://clinicaltrials.gov/study/NCT03044743","created_at":"2021-06-23T19:53:49.522Z","updated_at":"2024-07-02T16:37:22.878Z","phase":"Phase 1/2","brief_title":"PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies","source_id_and_acronym":"NCT03044743","lead_sponsor":"Yang Yang","biomarkers":" HLA-A • IFNG","pipe":" | ","alterations":" HLA-A*02 • HLA-A*11 • HLA-A*24","tags":["HLA-A • IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A*11 • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 04/07/2017","start_date":" 04/07/2017","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 03/01/2022","study_completion_date":" 03/01/2022","last_update_posted":"2017-05-02"}]